Psoriatic Arthritis Clinical Trial
Official title:
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis
Verified date | April 2024 |
Source | Aclaris Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
Status | Terminated |
Enrollment | 47 |
Est. completion date | January 3, 2024 |
Est. primary completion date | December 6, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Diagnosis of PsA with symptom onset at least 6 months before the Screening Visit and fulfilment of the Classification Criteria for PsA. - Patient has moderate-to-severe PsA at Screening and Randomization Visits defined as - =3 tender joints (based on 68 joint counts) and - =3 swollen joints (based on 66 joint counts). - Diagnosis of active plaque psoriasis or documented history of plaque psoriasis. Exclusion Criteria: - Any arthritis with onset before age 17 years, or current diagnosis of inflammatory joint disease other than PsA, or other immunological disease (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus). - Patient has an uncontrolled non-immunoinflammatory disease that may place the patient at increased risk during the study or impact the interpretation of results, eg, cirrhosis, previous malignancy, previous venous thromboembolism. - Any clinically significant laboratory abnormality that would affect interpretation of study data or safety of the patient's participation in the study, per judgment of the investigator. |
Country | Name | City | State |
---|---|---|---|
Poland | Aclaris Investigational Site | Bialystok | |
Poland | Aclaris Investigational Site | Bydgoszcz | |
Poland | Aclaris Investigational Site | Czestochowa | |
Poland | Aclaris Investigational Site | Katowice | |
Poland | Aclaris Investigational Site | Katowice | |
Poland | Aclaris Investigational Site | Kraków | |
Poland | Aclaris Investigational Site | Kraków | |
Poland | Aclaris Investigational Site | Olsztyn | |
Poland | Aclaris Investigational Site | Poznan | |
Poland | Aclaris Investigational Site | Stalowa Wola | |
Poland | Aclaris Investigational Site | Szczecin | |
Poland | Aclaris Investigational Site | Torun | |
Poland | Aclaris Investigational Site | Warszawa | |
Poland | Aclaris Investigational Site | Wroclaw | |
United States | Aclaris Clinical Operations | Charlotte | North Carolina |
United States | Aclaris Investigational Site | Duncansville | Pennsylvania |
United States | Aclaris Clinical Operations | Freehold | New Jersey |
United States | Aclaris Investigational Site | Memphis | Tennessee |
United States | Aclaris Investigational Site | Mesquite | Texas |
United States | Aclaris Investigational Site | Miami Lakes | Florida |
United States | Aclaris Investigational Site | Perrysburg | Ohio |
United States | Aclaris Investigational Site | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Aclaris Therapeutics, Inc. |
United States, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients achieving ACR20 at Week 12 | Baseline to Week 12 | ||
Secondary | Proportion of patients with ACR 50/70 at Week 12 | Baseline to Week 12 | ||
Secondary | Proportion of patients with ACR 20/50/70 response at weeks 2, 4, 6, 8 | Baseline to Week 12 | ||
Secondary | Change from baseline in tender joint count 68 at weeks 1, 2, 4, 6, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in swollen joint count 66 at weeks 1, 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in Health Assessment Questionnaire - Disability Index at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in patient's global assessment of disease activity at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in physician's global assessment of disease activity at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in Patients Pain VAS assessment at Weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in high sensitivity C-reactive protein (hs-CRP) at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in Leeds Enthesitis Index over 12 weeks | Baseline to Week 12 | ||
Secondary | Change from baseline in Leeds Dactylitis Index over 12 weeks | Baseline to Week 12 | ||
Secondary | Proportion of patients achieving at least a 30% reduction and at least 1 unit reduction from Baseline in the numerical rating scale (NRS30) in Patient's Daily Assessment of Skin Pain at Weeks 2, 4, 8, 12 among patients with Baseline NRS =3 | Baseline to Week 12 | ||
Secondary | Proportion of patients achieving a sIGA of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline among those with a baseline investigator's global assessment of at least 3 over 12 weeks | Baseline to Week 12 | ||
Secondary | Proportion of patients achieving MDA at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in DAS28CRP at Weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Psoriasis Area Severity Index (PASI) 50/75/90 response (for patients with =3% body surface area psoriasis at baseline) at Week 12 | Baseline to Week 12 | ||
Secondary | Mean change from baseline in PASI score at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in Short-Form-36 Physical Component Summary at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Change from baseline in Self-Assessment of Psoriasis Symptoms Questionnaire at weeks 2, 4, 8, 12 | Baseline to Week 12 | ||
Secondary | Type and frequency of adverse events | Baseline to Week 12 | ||
Secondary | Type and frequency of serious adverse events | Baseline to Week 12 | ||
Secondary | Zunsemetinib trough concentration ng/mL | Baseline to Week 12 | ||
Secondary | CDD-2164 metabolite trough concentration ng/mL | Baseline to Week 12 | ||
Secondary | Zunsemetinib peak concentration (Cmax) ng/mL | Baseline to Week 12 | ||
Secondary | CDD-2164 metabolite peak concentration (Cmax) ng/mL | Baseline to Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04152759 -
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT01925768 -
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT01892436 -
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT01212770 -
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01212757 -
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT03953378 -
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
|
||
Recruiting |
NCT02572700 -
Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
|
||
Completed |
NCT02556034 -
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02188654 -
Metformin in Psoriatic Arthritis
|
N/A | |
Completed |
NCT02164214 -
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
|
Phase 3 | |
Completed |
NCT01392326 -
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
|
Phase 3 | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 | |
Completed |
NCT00659412 -
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
|
Phase 2 | |
Completed |
NCT00946686 -
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT06059430 -
Cohort Project of Patients With Inflammatory Rheumatism
|